Additional Paid in Capital of Vitro Biopharma, Inc. from 31 Oct 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Vitro Biopharma, Inc. quarterly Additional Paid in Capital in USD history and change rate from 31 Oct 2010 to 31 Oct 2025.
  • Vitro Biopharma, Inc. Additional Paid in Capital for the quarter ending 31 Oct 2025 was $32,547,333, a 12% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $32,547,333 +$3,519,073 +12% 31 Oct 2025 10-K 13 Feb 2026 2025 FY
Q2 2025 $31,962,278 +$3,291,415 +11% 31 Jul 2025 10-Q 12 Sep 2025 2025 Q3
Q1 2025 $31,277,228 +$2,989,794 +11% 30 Apr 2025 10-Q 20 Jun 2025 2025 Q2
Q4 2024 $30,954,494 +$3,055,427 +11% 31 Jan 2025 10-Q 20 Mar 2025 2025 Q1
Q3 2024 $29,028,260 +$1,963,647 +7.3% 31 Oct 2024 10-K 13 Feb 2026 2025 FY
Q2 2024 $28,670,863 +$1,995,832 +7.5% 31 Jul 2024 10-Q 16 Sep 2024 2024 Q3
Q1 2024 $28,287,434 +$2,109,593 +8.1% 30 Apr 2024 10-Q 31 May 2024 2024 Q2
Q4 2023 $27,899,067 +$2,114,736 +8.2% 31 Jan 2024 10-Q 14 Mar 2024 2024 Q1
Q3 2023 $27,064,613 +$1,429,787 +5.6% 31 Oct 2023 10-K 28 Jan 2025 2024 FY
Q2 2023 $26,675,031 31 Jul 2023 10-Q 28 Aug 2023 2023 Q3
Q1 2023 $26,177,841 30 Apr 2023 10-Q 13 Jun 2023 2023 Q2
Q4 2022 $25,784,331 31 Jan 2023 10-Q 14 Mar 2023 2023 Q1
Q3 2022 $25,634,826 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q3 2015 $5,456,447 +$23,600 +0.43% 31 Oct 2015 10-K 22 Sep 2016 2015 FY
Q2 2015 $5,432,847 +$9,947 +0.18% 31 Jul 2015 10-Q 30 Mar 2016 2015 Q3
Q1 2015 $5,432,847 +$9,947 +0.18% 30 Apr 2015 10-Q 22 Jan 2016 2015 Q2
Q4 2014 $5,432,847 +$19,832 +0.37% 31 Jan 2015 10-Q 24 Mar 2015 2015 Q1
Q3 2014 $5,432,847 +$19,832 +0.37% 31 Oct 2014 10-K 22 Sep 2016 2015 FY
Q2 2014 $5,422,900 +$9,885 +0.18% 31 Jul 2014 10-Q 22 Sep 2014 2014 Q3
Q1 2014 $5,422,900 +$24,635 +0.46% 30 Apr 2014 10-Q 19 Jun 2014 2014 Q2
Q4 2013 $5,413,015 +$30,506 +0.57% 31 Jan 2014 10-Q 17 Mar 2014 2014 Q1
Q3 2013 $5,413,015 +$30,506 +0.57% 31 Oct 2013 10-K 13 Feb 2015 2014 FY
Q2 2013 $5,413,015 +$30,506 +0.57% 31 Jul 2013 10-Q 23 Sep 2013 2013 Q3
Q1 2013 $5,398,265 +$37,203 +0.69% 30 Apr 2013 10-Q 18 Jun 2013 2013 Q2
Q4 2012 $5,382,509 +$21,447 +0.4% 31 Jan 2013 10-Q 21 Mar 2013 2013 Q1
Q3 2012 $5,382,509 +$35,905 +0.67% 31 Oct 2012 10-K 12 Feb 2014 2013 FY
Q2 2012 $5,382,509 +$35,905 +0.67% 31 Jul 2012 10-Q/A 17 Oct 2012 2012 Q3
Q1 2012 $5,361,062 30 Apr 2012 10-Q/A 22 Jun 2012 2012 Q2
Q4 2011 $5,361,062 31 Jan 2012 10-Q 21 Mar 2012 2012 Q1
Q3 2011 $5,346,604 +$33,751 +0.64% 31 Oct 2011 10-K 12 Feb 2013 2012 FY
Q2 2011 $5,346,604 31 Jul 2011 10-Q/A 12 Oct 2011 2011 Q3
Q3 2010 $5,312,853 31 Oct 2010 10-K/A 16 Feb 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.